Prevalence of Non-AIDS Comorbidities and Factors Associated with Metabolic Complications among HIV-Infected Patients at a Thai Referral Hospital
| Autor: | Weerawat Manosuthi, Chotirat Nakaranurack |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Referral Anti-HIV Agents 030106 microbiology Immunology Human immunodeficiency virus (HIV) HIV Infections Hyperlipidemias Dermatology Comorbidity lcsh:RC870-923 medicine.disease_cause comorbidities 03 medical and health sciences 0302 clinical medicine Acquired immunodeficiency syndrome (AIDS) Metabolic Diseases Internal medicine Antiretroviral Therapy Highly Active medicine Prevalence Hiv infected patients Humans 030212 general & internal medicine Referral and Consultation Acquired Immunodeficiency Syndrome business.industry metabolic complications factors HIV Middle Aged lcsh:Diseases of the genitourinary system. Urology medicine.disease Thailand Antiretroviral therapy CD4 Lymphocyte Count Infectious Diseases Cross-Sectional Studies HIV-1 Female Original Article business |
| Zdroj: | Journal of the International Association of Providers of AIDS Care Journal of the International Association of Providers of AIDS Care, Vol 17 (2018) |
| ISSN: | 2325-9582 |
| Popis: | Objectives: The prevalence of non-AIDS-related comorbidities is increasing in HIV-infected patients receiving antiretroviral therapy. In Thailand, data regarding the prevalence of non-AIDS comorbidities and factors associated with metabolic complications in HIV-infected patients have not been well-documented. Methods: This cross-sectional study was conducted in 2011 and included 874 HIV-infected patients. Results: The age of patients was 45(8) years represented as mean (standard deviation [SD]). The current CD4 count was 502(247) cells/mm3. In all, 388 (44%) of the included patients had at least 1non-AIDS comorbidity. The most frequently documented comorbidities were hyperlipidemia in 271 (70%) patients. Using multivariate analysis, older age(odds ratio [OR] = 1.82, 95% confidence interval [CI] = 1.51-2.19), male sex (OR = 1.55, 95%CI = 1.14-2.11), high current CD4 count(OR = 1.00, 95%CI = 1.00-1.00), and taking abacavir (ABC)-containing(OR = 2.59, 95%CI = 1.16-5.78)and didanosine (ddI)-containing antiretroviral regimens (OR = 4.16, 95%CI = 1.09-15.84)were associated with the presence of metabolic complications (all PsConclusion: The prevalence of comorbidities is substantially high. Clinical monitoring and effective management of these comorbidities and metabolic complications are recommended, especially in HIV-infected patients who present with these associated factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|